showed an increased prevalence of mutations in CRBN and CRBN pathway genes (CRBN, CULB4, IRF4, IKZF1) in IMiDs (lenalidomide) refractory patients compared with newly diagnosed MM patients (58). This evidence concerns the gene IKZF1 and Miyoshi myopathy.